Serum epidermal growth factor receptor/HER‐2 predicts poor survival in patients with metastatic breast cancer
Authors:
- Kim LeitzelKLKim Leitzel
- Hilary A. Chaudri‐RossHCHilary A. Chaudri‐Ross
- Peter HamerPHPeter Hamer
Open Access
- 8 November 2006
- Vol. 107 (10) , 2337-2345
Abstract
BACKGROUND.: Epidermal growth factor receptor (EGFR, HER‐1, and erbB1) is overexpressed in primary breast cancer and had been identified as a poor prognostic factor.METHODS.: Pretreatment serum EGFR levels were quantified by using an enzyme‐linked immunoadsorbent assay in a Phase III first‐line trial of letrozole and tamoxifen and were correlated with patient outcomes.RESULTS.: Serum EGFR levels in a control group of 117 healthy, postmenopausal women measured 64.1 ± 13.3 ng/mL (mean ± standard deviation). Using a cutoff EGFR level of 44.1 ng/mL from the control group (5% nonparametric method), 53 of 535 patients (10%) had decreased serum levels of EGFR. Patients with decreased serum EGFR had no significant difference in objective response rate (ORR), clinical benefit rate (CBR), time to progression (TTP), or time to treatment failure (TTF); however, they did have significantly reduced survival compared with patients who had normal serum EGFR levels (median survival, 23.3 months vs. 30.9 months; P = .007). A combined analysis of pretreatment serum EGFR and HER‐2 yielded no additional predictive information for ORR, CBR, TTP, or TTF compared to serum HER‐2 alone. However, in the current analysis, a subgroup of patients who had decreased serum EGFR and normal serum HER‐2 was identified (n = 39 of 535 patients; 7.3%) that had significantly reduced survival compared with patients who had normal serum levels of both EGFR and HER‐2 (median survival, 23.5 months vs. 37.1 months; P = .005). In multivariate analysis, a decreased serum EGFR level remained a significant independent prognostic factor for decreased survival (hazards ratio, 1.58; P = .007).CONCLUSIONS.: In patients who had metastatic breast cancer, decreased serum EGFR/normal serum HER‐2 predicted shorter survival compared with patients who had normal levels of serum EGFR/HER‐2. This patient subgroup deserves further study to assess their response to and selection for anti‐EGFR‐directed therapies. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 36 references indexed in Scilit:
- Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung CancerClinical Cancer Research, 2004
- SRC gene expression in human cancer: the role of transcriptional activationBiochemistry and Cell Biology, 2004
- Elevated serum epidermal growth factor receptor level is correlated with lymph node metastasis in lung cancerInternational Journal of Clinical Oncology, 2003
- The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinomaInternational Journal of Gynecological Cancer, 2001
- The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinomaInternational Journal of Gynecological Cancer, 2001
- p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancerBritish Journal of Cancer, 1999
- Epidermal Growth Factor-related Peptides Activate Distinct Subsets of ErbB Receptors and Differ in Their Biological ActivitiesJournal of Biological Chemistry, 1996
- Elevated serum levels of transforming growth factor-α in breast cancer patientsCancer Letters, 1994
- Signal transduction by receptors with tyrosine kinase activityCell, 1990
- Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cellsNature, 1984